Scott M. Grundy scientist
Grundy, Scott M.
Grundy, Scott M., 1933-
Grundy, S.M.
VIAF ID: 65082847 (Personal)
Permalink: http://viaf.org/viaf/65082847
Preferred Forms
-
200 _ | ‡a Grundy ‡b Scott M.
-
100 1 _ ‡a Grundy, S.M.
-
-
-
-
-
-
-
-
100 1 _ ‡a Grundy, Scott M.
-
100 1 _ ‡a Grundy, Scott M.
-
100 1 _ ‡a Grundy, Scott M.
-
-
100 1 _ ‡a Grundy, Scott M. ‡d 1933-
-
-
100 0 _ ‡a Scott M. Grundy ‡c scientist
4xx's: Alternate Name Forms (6)
Works
Title | Sources |
---|---|
American heart association low-fat, low-cholesterol cookbook : an essential guide for those concerned about their cholesterol levels |
![]() ![]() ![]() ![]() ![]() ![]() |
Anti-Cholesterin-Diät |
![]() |
Atlas of atherosclerosis and metabolic syndrome |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
Cholesterol and atherosclerosis : diagnosis and treatment |
![]() ![]() ![]() |
Cholesterol-lowering therapy evaluation of clinical trial evidence |
![]() ![]() |
HMG CoA reductase inhibitors : a five-year clinical perspective : a symposium held November 12, 1989, in New Orleans, Louisana |
![]() |
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome |
![]() |
Lipoprotein kinetics and modeling, 1982 (a.e.) |
![]() ![]() ![]() ![]() ![]() |
Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia |
![]() |
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population |
![]() |
Mechanisms and treatment of dyslipidemia of renal diseases. |
![]() |
Mechanisms of disease: Ectonucleotide pyrophosphatase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors |
![]() |
Meta-analysis and imputation refines the association of 15q25 with smoking quantity |
![]() |
Metabolic syndrome phenotype in very obese women |
![]() |
The metabolic syndrome: practical guide to origins and treatment: Part I. |
![]() |
Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison of hypercholesterolemia alone and combined hyperlipidemia |
![]() |
New approaches to dietary management of elevated cholesterol : proceedings of an international conference held in Dublin, Ireland, 28-30 January 1999 |
![]() |
The place of HDL in cholesterol management. A perspective from the National Cholesterol Educational Program |
![]() |
Proceedings of a symposium : primary prevention of cardiovascular disease in high-risk patients |
![]() |
Quantitation of apolipoprotein B by chemical methods |
![]() |
Rationale and management of hyperlipidemia of the nephrotic syndrome. |
![]() |
Receitas de baixo teor de gordura e colesterol |
![]() |
Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia |
![]() |
Relationship between perceptions about neighborhood environment and prevalent obesity: data from the Dallas Heart Study |
![]() |
Relationship of apolipoprotein B levels to the number of risk factors for metabolic syndrome |
![]() |
Relationships of generalized and regional adiposity to insulin sensitivity in men. |
![]() |
Reply: Statin dose based on limited evidence. |
![]() |
Report of the Expert Panel on Awareness and Behavior Change to the Board of Directors, American Heart Association |
![]() |
Responsiveness of plasma lipids and lipoproteins to plant stanol esters |
![]() |
Role of apolipoprotein levels in clinical practice |
![]() |
Role of cholesterol in atherosclerosis : new therapeutic opportunities |
![]() ![]() ![]() ![]() ![]() ![]() |
Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: Evidence for heterogeneity. |
![]() |
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study) |
![]() |
Second international conference on fats and oil consumption in health and disease : how we can optimize dietary composition to combat metabolic complications and decrease obesity : proceedings of a symposium held at The University of Texas Southwestern Medical Center, Dallas, April 22-23, 1996 |
![]() ![]() |
Secondary Prevention for Atherosclerotic Cardiovascular Disease: Comparing Recent US and European Guidelines on Dyslipidemia |
![]() |
Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. |
![]() |
Serum lipids in the GENECARD study of coronary artery disease identify quantitative trait loci and phenotypic subsets on chromosomes 3q and 5q. |
![]() |
Sex differences in the association between leptin and CRP: results from the Dallas Heart Study. |
![]() |
Sex differences in the relationship between C-reactive protein and body fat. |
![]() |
Sex steroid hormones, upper body obesity, and insulin resistance. |
![]() |
Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? |
![]() |
Sources of variability in genetic association studies: insights from the analysis of hepatic lipase (LIPC). |
![]() |
Studied of very low density lipoprotein triglyceride metabolism in an obese population with low plasma lipids: lack of influence of body weight or plasma insulin. |
![]() |
Studies on mechanisms for enhanced clearance of low-density lipoproteins in patients with primary hypertriglyceridaemia |
![]() |
A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines |
![]() |
Summary of the scientific conference on dietary fatty acids and cardiovascular health: conference summary from the nutrition committee of the American Heart Association |
![]() |
Temporal decline in non-high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease |
![]() ![]() |
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. |
![]() |
Translation of nutritional sciences into medical education: the Nutrition Academic Award Program. |
![]() |
Treatment of dyslipidemia in non-insulin-dependent diabetes mellitus with lovastatin |
![]() |
Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol |
![]() |
Trends in serum lipids and lipoproteins of adults, 1960-2002. |
![]() |
Triglyceride-to-high-density-lipoprotein-cholesterol ratio is an index of heart disease mortality and of incidence of type 2 diabetes mellitus in men. |
![]() |
Upper body fat predicts metabolic syndrome similarly in men and women |
![]() |
Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in various forms of dyslipidemia |
![]() |
Variability in cholesterol content and physical properties of lipoproteins containing apolipoprotein B-100 |
![]() |
Variable contributions of fat content and distribution to metabolic syndrome risk factors |
![]() |
Variation at the hepatic lipase and apolipoprotein AI/CIII/AIV loci is a major cause of genetically determined variation in plasma HDL cholesterol levels |
![]() |
Varying susceptibility of different low density lipoproteins to oxidative modification. |
![]() |
Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines |
![]() |
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials |
![]() |
Waist circumference as measure of abdominal fat compartments |
![]() |
What is Meant by Overproduction of Apo B-Containing Lipoproteins? |
![]() |
When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction |
![]() |